文献速递姑息放疗与转移瘤放疗物理与技术

STAT RAD:单次扫描-计划-QA-治疗SBRT治疗骨转移的前瞻性剂量递增试验

STAT RAD: Prospective Dose Escalation Clinical Trial of Single Fraction Scan-Plan-QA-Treat Stereotactic Body Radiation Therapy for Painful Osseous Metastases.
PubMed 文献 · Pract Radiat Oncol · 2020-04-11

这项1/2期前瞻性剂量递增试验评估了同日完成CT模拟、计划、QA和治疗的STAT RAD工作流,对1-3处疼痛性骨转移患者行单次8-15 Gy立体定向放疗。46例患者60处病灶可评估,1周和8周疼痛缓解率分别为50%和75%,2例3级毒性,16.7%病灶需再放疗,多数患者愿再次选择该流程。

要点

  • 单次8-15 Gy STAT RAD工作流可行且安全,疼痛缓解早期显著。
  • 1周和8周疼痛缓解率分别为50%和75%,但12个月降至33.3%。
  • 3级毒性2例,再放疗率16.7%,中位再治疗时间4.9个月。

核心结论

  • 单次STAT RAD工作流治疗疼痛性骨转移可行且安全,剂量可达15 Gy。
  • 12个月疼痛缓解下降且再治疗率16.7%,提示需进一步剂量递增。

研究设计与样本

  • 前瞻性1/2期剂量递增临床试验,纳入1-3处疼痛性骨转移患者。
  • 采用同日Scan-Plan-QA-Treat工作流行单次SBRT,剂量从8 Gy递增至15 Gy。
  • 共49例入组,46例60处病灶按方案治疗,评估疼痛、阿片使用、满意度及毒性。

主要发现

  • 部分或以上疼痛缓解率:1周50%、8周75%、6个月68.7%、12个月33.3%。
  • 出现2例3级毒性,包括1例与疾病进展相关的脊柱骨折及高胆红素血症。
  • 16.7%的治疗病灶需再放疗,中位再治疗时间4.9个月。
  • 78.6%的患者表示愿意再次选择该工作流。

临床怎么用

  • 可考虑对1-3处疼痛性骨转移患者采用单次STAT RAD工作流行姑息SBRT。
  • 剂量递增至15 Gy可行,但需关注12个月疼痛缓解下降及再治疗可能。

局限性

  • 为前瞻性单臂 pilot 试验,样本量有限(46例可评估)。
  • 疼痛缓解在12个月下降,长期疗效需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiation therapy is a well-established treatment for symptomatic bone metastases. Despite continued advances in both planning techniques and treatment delivery, the standard workflow has remained relatively unchanged, often requiring 1 to 3 weeks and resulting in patient inconvenience and delayed palliation. We developed an expedited method wherein computed tomography simulation, treatment planning, quality assurance, and treatment delivery are performed in 1 day. This prospective pilot clinical trial evaluates the safety, efficacy, and patient satisfaction of this rapid workflow. METHODS AND MATERIALS: Patients with 1 to 3 painful bone metastases were prospectively enrolled and treated with 1 fraction of stereotactic body radiation therapy, using a same-day Scan-Plan-QA-Treat workflow, termed STAT RAD, in a phase 1/2 dose escalation trial from 8 Gy to 15 Gy per fraction. Bone pain, opioid use, patient satisfaction, performance status, and quality of life were evaluated before and at 1, 4, 8, 12, 26, and 52 weeks after treatment. Outcomes and treatment-related toxicity were analyzed. RESULTS: A total of 49 patients were enrolled, and 46 patients with 60 bone metastases were treated per the protocol. Partial or greater pain response occurred in 50% of patients at 1 week, 75% of patients at 8 weeks, 68.7% of patients at 6 months, and 33.3% of patients at 12 months. There were 2 grade-3 toxicities, including 1 spinal fracture associated with disease progression and hyperbilirubinemia. Reirradiation was required in 16.7% of treated lesions at a median time to retreatment of 4.9 months. Most patient responses (78.6%) indicated that patients would choose this workflow again. CONCLUSIONS: The results demonstrate that treating bone metastases with palliative stereotactic body radiation therapy via a single-fraction, patient-centric workflow is feasible and safe with doses up to 15 Gy. However, pain response decreased at 12 months and was associated with a 16.7% retreatment rate, which suggests that further dose escalation is warranted.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Muller DA, Wages NA, Wilson DD, et al. STAT RAD: Prospective Dose Escalation Clinical Trial of Single Fraction Scan-Plan-QA-Treat Stereotactic Body Radiation Therapy for Painful Osseous Metastases. Pract Radiat Oncol. 2020. PMID: 32289551. doi:10.1016/j.prro.2020.03.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。